# 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

> **NCT01163383** · — · AVAILABLE · sponsor: **John Maris**

## Conditions studied

- Neuroblastoma
- Childhood Metastatic Pheochromocytoma

## Interventions

- **DRUG:** 131 I-Metaiodobenzylguanidine (131 I-MIBG)
- **DRUG:** 131 I-MIBG

## Key facts

- **NCT ID:** NCT01163383
- **Lead sponsor:** John Maris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163383, "131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01163383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*